Preclinical Studies of Novel Anti-Diabetic Lipids
新型抗糖尿病脂质的临床前研究
基本信息
- 批准号:9515379
- 负责人:
- 金额:$ 90.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-04 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdipocytesAdipose tissueAgonistAnti-Inflammatory AgentsAnti-inflammatoryAntidiabetic DrugsBiologicalBiological AssayBiological AvailabilityBiologyBlood GlucoseCellsChemicalsChronicClinicClinical DataClinical TrialsDataDendritic CellsDevelopmentDiabetes MellitusDiabetes preventionDiseaseDoseDrug KineticsDrug TargetingEffectivenessEpidemicEstersFamilyFastingFatty AcidsG-Protein-Coupled ReceptorsGCG geneGenetically Engineered MouseGlucoseGoalsHalf-LifeHigh Fat DietHumanInflammationInsulinInsulin ResistanceIslets of LangerhansIsomerismKnockout MiceKnowledgeLeadLigandsLipidsMeasurementMediatingMetabolicMetabolic DiseasesMolecularMusNon-Insulin-Dependent Diabetes MellitusObese MiceObesityOralPalmitic AcidsPathway interactionsPharmaceutical PreparationsPositioning AttributePrevention strategyProcessPropertyRoleSafetyScheduleSerumSolubilityStearic AcidsStructureStructure-Activity RelationshipTestingTherapeuticTissuesToxic effectToxicologyWorkanalogbaseclinical developmentcytokinedesigndiabeticdrug developmenteffective therapyexperimental studyglucose metabolismglucose toleranceglucose transporthydroxy fatty acidimprovedin vivoinsightinsulin secretagoguesinsulin secretioninsulin sensitivityinsulin sensitizing drugsinterestmacrophagemetabolic abnormality assessmentnext generationnovelpre-clinicalpreclinical studypreventreceptorscreeningsmall moleculetreatment strategy
项目摘要
Because of the growing epidemic of obesity, insulin resistance, and Type 2 diabetes, we need more effective and sustainable prevention and treatment strategies for these serious disorders. Significant gaps exist in our knowledge of the molecular mechanisms underlying insulin resistance and Type 2 diabetes, which limit our ability to develop fully effective and safe therapies to treat these metabolic diseases. In this application, we strive to develop a new class of antidiabetic therapeutics based on a structurally novel class of bioactive lipids we recently discovered called Fatty Acid esters of Hydroxy Fatty Acids (FAHFAs). Characterization of one family of FAHFAs, Palmitic Acid esters of Hydroxy Stearic Acids (PAHSAs), revealed that these lipids possess a remarkable range of activities that improve glucose metabolism and reduce inflammation. PAHSAs stimulate insulin secretion and GLP1 secretion, improve systemic insulin sensitivity (i.e. they are insulin sensitizers), and reduce proinflammatory cytokine secretion in adipose tissue of obese mice. As natural compounds, PAHSAs were not designed for a particular target. Instead, these lipids utilize multiple pathways through at least two G protein coupled receptors (GPCRs). This powerful combination of beneficial activities and receptor targets uniquely positions PAHSAs as an exciting new class of compounds for the treatment of diabetes. In Aim 1, we will design, synthesize, and test PAHSAs and PAHSA analogs to enhance solubility, biological activity, and metabolic stability. This process will be iterative as we synthesize PAHSA analogs we will test them in biologic assays and metabolic stability studies in Aims 1 and 2 and use this information to design the next generation of analogs with improved properties. In Aim 2, we will investigate pharmacokinetics, efficacy, and toxicity of PAHSAs and PAHSA analogs to determine which compounds have the ideal stability, oral availability, safety, and activity. The information from these experiments will also assist in the design of new PAHSA analogs in Aim 1. Then in Aim 3, we will determine the roles of GPR40 and GPR120 in mediating PAHSA biological effects in vivo using knockout mice and biologic assays in tissues from these mice. A clear mechanism of action is required for drugs moving into the clinic, and the finding that PAHSAs target two intensely pursued anti-diabetic GPCR drug targets will amplify interest in developing PAHSA-based drugs. We will also perform broad target screening since PAHSAs might have additional receptors or pathways. The combination of the data obtained in Aim 3 will provide a comprehensive understanding of the contribution of GPR40, GPR120, and other PAHSA targets to PAHSA biology in vivo. This application will provide the structural, pharmacokinetic, toxicology, and mechanistic data needed to develop PAHSAs or PAHSA analogs into novel anti-diabetes therapeutics.
由于肥胖症,胰岛素抵抗和2型糖尿病的流行病,我们需要对这些严重疾病的更有效和可持续的预防和治疗策略。我们对胰岛素抵抗和2型糖尿病的分子机制的了解存在很大的差距,这限制了我们开发完全有效且安全的治疗这些代谢疾病的能力。在此应用中,我们努力根据我们最近发现的称为羟基脂肪酸(Fahfas)的脂肪酸酯(FAHFAS)的结构新型生物活性脂质开发新的抗糖尿病治疗剂。羟基酸(PAHSA)的一个Fahfas,棕榈酸酯的表征表明,这些脂质具有改善葡萄糖代谢并减少炎症的显着活性。 PAHSA刺激胰岛素分泌和GLP1分泌,提高全身性胰岛素敏感性(即它们是胰岛素敏感性),并减少肥胖小鼠脂肪组织中促炎细胞因子分泌。作为天然化合物,PAHSA不是为特定目标设计的。相反,这些脂质通过至少两个G蛋白偶联受体(GPCR)利用多个途径。这种有益的活动和受体的强大组合将PAHSA唯一的位置作为一种令人兴奋的新化合物,用于治疗糖尿病。在AIM 1中,我们将设计,合成和测试PAHSA和PAHSA类似物,以增强溶解度,生物活性和代谢稳定性。当我们合成PAHSA类似物时,我们将在AIMS 1和2中的生物学测定和代谢稳定性研究中对其进行测试,这将是迭代的。在AIM 2中,我们将研究PAHSA和PAHSA类似物的药代动力学,功效和毒性,以确定哪些化合物具有理想的稳定性,口服可用性,安全性和活性。这些实验的信息还将在AIM 1中有助于设计新的PAHSA类似物。然后,在AIM 3中,我们将确定GPR40和GPR120在使用基因敲除小鼠中使用敲除小鼠和生物学测定中的PAHSA生物学作用在这些小鼠中的生物学分析中的作用。进入诊所的药物需要一种明确的作用机理,而PAHSA的目标是两个强烈追求抗糖尿病GPCR药物靶标的发现将扩大对开发基于PAHSA的药物的兴趣。我们还将进行广泛的目标筛选,因为PAHSA可能具有其他受体或途径。 AIM 3中获得的数据的组合将对GPR40,GPR120和其他PAHSA靶标的对PAHSA生物学的贡献进行全面了解。该应用将提供结构性,药代动力学,毒理学以及将PAHSA或PAHSA类似物开发为新型抗糖尿病疗法所需的机械数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BARBARA B. KAHN其他文献
BARBARA B. KAHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BARBARA B. KAHN', 18)}}的其他基金
Mechanisms for regulation of a novel class of anti-diabetic lipids
一类新型抗糖尿病脂质的调节机制
- 批准号:
10378154 - 财政年份:2016
- 资助金额:
$ 90.31万 - 项目类别:
Regulation of the biosynthesis of a novel class of anti-diabetic lipids
一类新型抗糖尿病脂质生物合成的调节
- 批准号:
9895741 - 财政年份:2016
- 资助金额:
$ 90.31万 - 项目类别:
Mechanisms for regulation of a novel class of anti-diabetic lipids
一类新型抗糖尿病脂质的调节机制
- 批准号:
10609856 - 财政年份:2016
- 资助金额:
$ 90.31万 - 项目类别:
INTERPLAY OF TRANSTHYRETIN AND RETINOL BINDING PROTEIN IN TYPE 2 DIABETES
转甲状腺素蛋白和视黄醇结合蛋白在 2 型糖尿病中的相互作用
- 批准号:
8365542 - 财政年份:2011
- 资助金额:
$ 90.31万 - 项目类别:
INTERPLAY OF TRANSTHYRETIN AND RETINOL BINDING PROTEIN IN TYPE 2 DIABETES
转甲状腺素蛋白和视黄醇结合蛋白在 2 型糖尿病中的相互作用
- 批准号:
8170910 - 财政年份:2010
- 资助金额:
$ 90.31万 - 项目类别:
相似国自然基金
脂肪干细胞外泌体miRNA-299a-3p调控巨噬细胞Thbs1缓解脂肪组织衰老的机制研究
- 批准号:82301753
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
CXCL1/CXCR2信号轴上调Bcl-2促进筋膜定植巨噬细胞迁移在皮下脂肪组织原位再生中的机制研究
- 批准号:82360615
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
Arid5b调控Treg细胞脂肪组织适应性发育和代谢调控功能及机制探究
- 批准号:82371752
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
巨噬细胞Lp-PLA2对脂肪组织重塑的调控及其作用机制
- 批准号:32300977
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
巨噬细胞介导脂肪组织重构在塑化剂干扰系统能量代谢中的作用研究
- 批准号:82373625
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Assessing the Impact of SARS-CoV-2 on Adipose Tissue Function and Glucose Homeostasis
评估 SARS-CoV-2 对脂肪组织功能和血糖稳态的影响
- 批准号:
10682138 - 财政年份:2023
- 资助金额:
$ 90.31万 - 项目类别:
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease
肥胖对 SARS-COV-2 感染的影响以及 SARS-COV-2 对代谢疾病的相互影响
- 批准号:
10583175 - 财政年份:2023
- 资助金额:
$ 90.31万 - 项目类别:
Investigating Isthmin as an adipose-to-muscle messenger that promotes muscle protein synthesis
研究 Isthmin 作为促进肌肉蛋白质合成的脂肪到肌肉信使
- 批准号:
10664500 - 财政年份:2023
- 资助金额:
$ 90.31万 - 项目类别:
Assessing the Impact of SARS-CoV-2 on Adipose Tissue Function and Glucose Homeostasis
评估 SARS-CoV-2 对脂肪组织功能和血糖稳态的影响
- 批准号:
10835381 - 财政年份:2023
- 资助金额:
$ 90.31万 - 项目类别:
Mechanisms of adipocyte loss in mouse models of familial partial lipodystrophy 2
家族性部分脂肪营养不良小鼠模型脂肪细胞丢失的机制2
- 批准号:
10748790 - 财政年份:2023
- 资助金额:
$ 90.31万 - 项目类别: